Table 1 Comparison of RECIST 1.1, iRECIST, PERCIST, and iPERCIST criteria for immunotherapy evaluation
RECIST 1.1 | iRECIST | PERCIST | iPERCIST | |
|---|---|---|---|---|
Complete response | Disappearance of all target and non-target lesions nodes, must regress to < 10 mm in the short axis | Complete resolution of FDG uptake within the target lesion | ||
Partial response | ≥ 30% decrease in tumor burden compared to baseline (largest diameter in axial plane) | ≥ 30% decrease in the target tumor FDG SULpeak | ||
Stable disease | Neither partial response, complete response nor progressive disease | Neither partial response, complete response nor progressive disease | ||
Disease progression | ≥ 20% + 5 mm absolute increase in tumor burden compared with nadir. Appearance of new lesions or progression of non-target lesions | ≥ 20% + 5 mm absolute increase in tumor burden compared with nadir. Appearance of new lesions or progression of non-target lesions. (iUPD) Need to be confirmed 4–8 weeks later (iCPD); if progression is followed by tumor shrinkage, the bar is reset. Clinical stability is considered when deciding whether treatment is continued after iUPD | ≥ 30% increase in FDG SULpeak or advent of new 18F-FDG-avid lesions | ≥ 30% increase in FDG SULpeak or advent of new 18F-FDG-avid lesions (UPMD) Need to be confirmed by a second PET at 4–8 weeks later (CPMD); if progression is followed by PMR or SMD, the bar is reset. Clinical stability is considered when deciding whether treatment is continued after UPMD |